Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
NSRX · NYSE American · Pharmaceutical Preparations · Foreign private issuer
Nasus Pharma (NSRX) · oqro.io/stocks/NSRX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.66−0.21 (−7.32%)
Close of Nov 16, 2026, vs Nov 13 · end-of-day, not a live quote
No open-market purchase by an insider of Nasus Pharma was filed in the last 90 days. The latest on record was on Jun 22, 2026.
Since 2026, Nasus Pharma insiders reported 3 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2026.
No open-market sale by an insider of Nasus Pharma (NSRX) was filed with the SEC in the last 90 days.
No trade in Nasus Pharma (NSRX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−62.2% (−$4.37) from Nov 17, 2025 to Nov 16, 2026 · adjusted daily closes
Adjusted close went from $7.03 on Nov 17, 2025 to $2.66 on Nov 16, 2026 (−62.2%). Disclosed in this range: 3 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 2 13F position changes for 2 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Tel Aviv - Yafo, Israel. Foreign private issuer: reports on Form 20-F or 40-F.
Pharmaceutical Preparations company based in Tel Aviv - Yafo, Israel. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
−64.1%
Market value
$24M
S&P 500 +10.1% over the same dates. Prices adjusted for splits and dividends.
Short interest: 71K shares sold short (0.8% of shares outstanding), −11.7% vs the previous count, 3.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue, fiscal 2025
$1.24B
Year ended Dec 31, 2025
Net income, fiscal 2025
−$5.86M
A loss for the year
Shares outstanding
9.02M
As of Dec 31, 2025
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Insider buying
Traded Jun 17 · filed 5 days later
Since the trade −13.6% · S&P 500 −0.1% · to Nov 16
The CEO of Nasus Pharma paid $20K out of pocket for Nasus Pharma shares.
Fund moves
Among this manager's largest new positions for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Insider buying
Traded Apr 22 · filed 1 day later
Since the trade −31.6% · S&P 500 +4.0% · to Nov 16
The CEO of Nasus Pharma paid $11K out of pocket for Nasus Pharma shares.
Insider buying
Traded Mar 31 · filed 1 day later
Since the trade +19.8% · S&P 500 +13.8% · to Nov 16
The CEO of Nasus Pharma paid $31K out of pocket for Nasus Pharma shares. Shares held went up 240% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Nasus Pharma reported 3 open-market purchases and 0 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $62K3×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
1 active phase 3 trial and 1 active phase 2 trial led by this company, mostly in anaphylaxis, anaphylaxis food.
2 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Against the S&P 500 over the year
Since Oct 28, 2025, NSRX is down 68.3% and the index fund is up 7.7%: 76 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much NSRX moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.